Explained — Why Natco Pharma shares surged up to 5% on Friday
Published on 10/10/2025 09:51 AM
Explained — Why Natco Pharma shares surged up to 5% on FridayThe latest ruling clears the path for Natco to launch its generic version of the drug used in the treatment of Spinal Muscular Atrophy immediately.By Ekta Batra October 10, 2025, 9:51:00 AM IST (Published)1 Min ReadShares of Natco Pharma Ltd. surged up to 5% on Friday, October 10, in response to the Delhi High Court upholding an earlier order, allowing the company to sell a generic version of Swiss drugmaker Roche's spinal muscular atrophy (SMA) drug Risdiplam in India.
A division bench dismissed Roche’s appeal against a March 2025 single-judge order that had denied an injunction on public interest grounds, noting that the life-saving therapy must remain affordable and accessible.
Sold under the brand name Evrysdi by Roche, Risdiplam is used to treat SMA, a rare genetic disorder that causes progressive muscle weakness and loss of motor function. The latest ruling clears the path for Natco to launch its generic version immediately.
In a statement, Natco said it would release the product at a maximum retail price of ₹15,900 per bottle, a steep reduction from Roche’s imported version priced at around ₹6 lakh. The company added that it plans to offer additional discounts through a patient access programme to make the medicine even more affordable for eligible patients.
Shares of Natco Pharma are trading 4% higher on Friday at ₹845.3. The stock is flat over the last one month, but is down over 45% from its 52-week high of over ₹1,500 per share.Continue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsNatco Pharmashare market today